Full Text View
Tabular View
No Study Results Posted
Related Studies
Herbal Treatment of Hepatitis C in Methadone Maintained Patients
This study has been completed.
Study NCT00010816   Information provided by National Center for Complementary and Alternative Medicine (NCCAM)
First Received: February 2, 2001   Last Updated: August 17, 2006   History of Changes

February 2, 2001
August 17, 2006
September 1998
 
 
 
Complete list of historical versions of study NCT00010816 on ClinicalTrials.gov Archive Site
 
 
 
Herbal Treatment of Hepatitis C in Methadone Maintained Patients
Herbal Treatment of Hepatitis C in Methadone Maintained Patients

Hepatitis C (HCV) is a chronic viral illness leading to progressive liver damage that has emerged as a major public health issue in the United States. While HCV affects all population groups, individuals with a history of intravenous drug use form the largest known risk group. Between 90 and 100 percent of long term intravenous drug use will eventually test positive for HCV, and there is substantial risk that even short term experimentation will result in infection. Studies suggest that HCV will be the major cause of cirrhosis and liver cancer in the next century. Currently, approved therapy includes recombinant interferons, which lead to sustained remission in a minority of patients. However, patients abusing other substances, including alcohol, are not eligible for interferon therapy. The need for investigation into other potential therapies is clear. Current practice patterns in the Far East include the use of traditional herbal remedies for symptomatic chronic viral hepatitis. This study is intended to examine the effect of commonly used herbal remedies for the treatment of symptomatic HCV.

 
Phase II
Interventional
Treatment, Randomized, Double-Blind, Placebo Control
Hepatitis C
Drug: Herbal remedies
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
 
June 2003
 

Inclusion Criteria:

  • English speaking/reading
  • Serum positive for HCV virus by PCR
  • Elevated alanine transferase (ALT) within 6 months of the Entry Visit, unattributable to causes other than HCV
  • Liver biopsy within 2 years of entry confirming that the histological diagnosis is consistent with chronic HCV
  • Laboratory parameters available at the Entry Visit including CBC, differential, and platelet count.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00010816
 
P50 AT000009-02P3, P50 AT000009-02, P50 AT000009-03
National Center for Complementary and Alternative Medicine (NCCAM)
 
Principal Investigator: Jeff Albrecht, MD Hennepin County Medical Center, Minneapolis
National Center for Complementary and Alternative Medicine (NCCAM)
August 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP